IDH1 and central nervous system cancer: A well-recognized oncometabolite is 2-HG, resulting from mutations in the isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) enzymes in gliomas and acute myeloid leukemia (AML) (Figure 1) [34].